Sun Yat-sen University

This study tests whether a blood test that detects tiny bits of tumor DNA can help doctors decide who needs extra immunotherapy (toripalimab) after lung cancer surgery. About 80 adults with stage IB-IIIA non-small-cell lung cancer will receive treatment based on their blood test …

This study looks at whether early heart monitoring and treatment can help people with advanced lung cancer who are receiving strong cancer therapies. About 524 adults with stage III non-small cell lung cancer will be enrolled. The goal is to see if this approach improves survival…

This study compares two modern surgical methods for treating low rectal cancer: transanal total mesorectal excision (taTME) and robot-assisted surgery (RTME). The goal is to see which approach leads to fewer complications and better recovery. About 216 adults with newly diagnosed…

This study tests whether a special low-calorie diet that mimics fasting can make standard chemo-immunotherapy work better for people with early-stage triple-negative breast cancer. About 80 participants will follow the diet before and during treatment. The main goal is to see if …

This study looks at men whose prostate cancer has spread to nearby lymph nodes after surgery. It compares two treatments: hormone therapy alone versus hormone therapy plus radiation to the pelvis. The goal is to see if adding radiation can keep the cancer from coming back or spre…

This study tests a drug called becotatug vedotin in people with advanced nasopharyngeal cancer whose tumors didn't shrink enough after standard chemo-immunotherapy. About 59 adults will receive the drug during and after radiation therapy. The goal is to see if this approach can p…

This phase 3 trial aims to see if adding chemotherapy (cisplatin) to standard radiation therapy after surgery helps people with intermediate-risk head and neck squamous cell carcinoma live longer without the cancer returning. About 386 participants who have had surgery and show c…

This study looks at whether people with advanced head and neck cancer who had a good response to chemo-immunotherapy before surgery can safely avoid low-dose radiation to the neck afterward. The goal is to maintain cancer control while reducing side effects and improving quality …

This study tests a combination of two drugs, toripalimab and celecoxib, in people with a specific genetic type of advanced colorectal cancer (dMMR/MSI-H). The goal is to see if the treatment can make the cancer disappear completely, allowing some patients to avoid surgery. About …

This study tests whether adding the immunotherapy drug adebrelimab to standard chemotherapy before surgery can help people with a certain type of esophageal cancer. The goal is to make the tumor easier to remove completely, lower the chance of cancer coming back, and improve surv…

This study is for people with nasopharyngeal cancer that has spread to other parts of the body. Researchers want to see if waiting to give radiation to the head and neck area (only if needed later) works as well as giving it right away, after initial treatment with a PD-1 inhibit…

This study tests whether adding two extra drugs (envafolimab and a stronger chemo mix) to standard treatment can help people with a specific type of advanced colorectal cancer live longer without the disease getting worse. About 198 adults with left-sided, RAS/BRAF wild-type, MSS…

This study tests a combination of two drugs (Sac-TMT and Tagitanlimab) in 35 people with a specific type of advanced breast cancer that is hormone receptor-positive, HER2-negative, and PD-L1-positive. Participants must have already been treated with a CDK4/6 inhibitor. The goal i…

This study tests whether adding the drug selinexor to standard chemotherapy (R-CHOP) can improve outcomes for people with a specific, hard-to-treat type of lymphoma (TP53-mutated DLBCL) who have not had prior treatment. About 42 adults aged 18-80 will receive the combination, fol…

This phase 3 trial tests whether adding two drugs—toripalimab (an immunotherapy) and capecitabine (a chemotherapy pill)—after standard chemoradiation can help prevent esophageal cancer from coming back. About 242 adults with advanced esophageal cancer who have not worsened after …

This study tests a new combination of drugs and radiation for people with advanced esophageal cancer that cannot be removed by surgery. The treatment includes surufatinib, immunotherapy, chemotherapy, and radiation. The goal is to see if this approach can stop the cancer from gro…

This study tests a new drug (trastuzumab rezetecan) alone or with an immunotherapy (adebrelimab) for people with advanced bladder cancer that has spread and shows HER2 protein. About 96 adults with HER2-positive urothelial carcinoma will receive the treatment to see if tumors shr…

This study tests whether a structured nutrition plan helps patients with advanced nasopharyngeal cancer who are already malnourished. About 266 adults aged 18-65 will receive either standard nutrition therapy or usual care during cancer treatment. The goal is to see if better nut…

This study tests a combination of three drugs (chidamide, sintilimab, and bevacizumab) in 34 people with advanced extrapulmonary neuroendocrine carcinoma that has stopped responding to standard first-line treatment. The goal is to see if this combination can shrink tumors or slow…

This study tests two different chemotherapy combinations for people with metastatic colorectal cancer that has spread and needs a second treatment. About 280 adults will be randomly assigned to receive either FOLFIRI or irinotecan, with or without bevacizumab. The goal is to see …

This study is for people aged 60 and older with advanced melanoma that cannot be removed by surgery or has spread. It tests whether adding thymosin alpha 1 to a standard immunotherapy drug (anti-PD-1) can improve tumor shrinkage and reduce side effects. Participants receive both …

This study tests a new drug called QL1706 in 45 adults with advanced bone or soft tissue sarcoma that cannot be removed by surgery or has spread. Participants receive the drug every 3 weeks. The main goal is to see if the cancer stays stable for at least 12 weeks. Researchers wil…

This study tests whether adding an immunotherapy drug (anti-PD-1 antibody) to standard chemoradiotherapy helps people with nasopharyngeal cancer that has come back after initial treatment. About 212 adults whose cancer cannot be surgically removed will be randomly assigned to rec…

This study tests a new treatment for people whose nasopharyngeal cancer has come back or spread. It combines two types of radiation (SBRT and LDRT) with an immunotherapy drug (PD-1 antibody) and chemotherapy. The goal is to see if this mix can control the cancer longer and with m…

This study is for people with stage III nasopharyngeal cancer whose tumors respond well to initial treatment. It tests whether a lower dose of radiation, combined with chemotherapy and immunotherapy, can control the cancer just as well as the standard higher dose, while causing f…

This study tests whether giving chemotherapy directly into the liver along with an immunotherapy drug (tislelizumab) before surgery, followed by more immunotherapy after surgery, can prevent liver cancer from coming back. It involves 39 adults with high-risk liver cancer that is …

This study is for people with peripheral T-cell lymphoma (a rare blood cancer) that has returned or not improved after standard treatment. Researchers are testing a new combination of drugs (golidocitinib plus either mitoxantrone liposome or chidamide) to see if it can shrink tum…

This phase 3 trial tests whether adding immunotherapy to standard treatment can improve outcomes for people with advanced nasopharyngeal cancer. About 802 participants will be split into low-risk and high-risk groups to see if personalized treatment can reduce side effects and pr…

This study tests a new combination of drugs (iparomlimab, tuvonralimab, chemotherapy, and lenvatinib) as a second-line treatment for people with advanced bile duct cancer that has worsened after first-line therapy. The goal is to see if this approach can help control the cancer a…

This study tests whether adding low-dose radiation to a standard chemotherapy plus immunotherapy combination can help control advanced nasopharyngeal cancer that has returned or spread. About 55 adults aged 18-65 with this specific cancer type will receive the treatment. The goal…

This study is for people with advanced triple-negative breast cancer that cannot be removed by surgery. It tests different ways of combining radiation therapy with immunotherapy to see which works best to control the cancer. The goal is to keep the cancer from growing for as long…

This study tests whether giving two drugs (sintilimab and bevacizumab) before surgery can lower the chance of liver cancer coming back. It involves 37 adults with resectable liver cancer that is beyond standard transplant criteria. The goal is to see if this approach improves 1-y…

This study tests whether adding a short course of radiation to a mix of immunotherapy (iparomlimab and tuvonralimab), a targeted drug (regorafenib), and chemotherapy (CAPOX) can better shrink advanced rectal cancer before surgery. About 88 adults with a specific type of rectal ca…

This study tests whether giving targeted drugs before surgery can help people with stage III lung cancer that has rare gene changes. About 120 adults who have not had treatment will receive a drug matched to their tumor's mutation, then doctors will check if the tumor becomes rem…

This study tests whether adding immunotherapy to standard chemotherapy and radiation, followed by maintenance immunotherapy, works better than a standard maintenance drug (capecitabine) for people with high-risk nasopharyngeal cancer. About 142 adults aged 18-70 with advanced dis…

This study tests a combination of three drugs (pucotenlimab, lenvatinib, and irinotecan) in children aged 2-18 with advanced hepatoblastoma that has not responded to prior treatment. The goal is to see if this approach can slow or stop cancer growth. Up to 24 children will receiv…

This study tests whether freezing tumors (cryoablation) combined with an immunotherapy drug (camrelizumab) can shrink advanced soft tissue sarcomas that have stopped responding to standard treatments. About 57 participants aged 14 to 70 will receive this combination. The main goa…

This study tests whether adding the immunotherapy drug sintilimab to standard chemotherapy can help people with a rare and aggressive type of lymphoma (NK/T-cell lymphoma) that has spread. About 84 newly diagnosed patients will be randomly assigned to receive either the combinati…

This study tests whether a combination of two experimental drugs (iparomlimab and tuvonralimab) plus standard chemotherapy and a targeted therapy can shrink tumors in adults with a specific type of advanced colorectal cancer (BRAF V600E mutation). About 20 people whose cancer has…

This study tests a new approach for people with a common type of locally advanced rectal cancer. It combines low-dose radiation, an immunotherapy drug (pucotenlimab), and chemotherapy before surgery. The goal is to shrink or eliminate the tumor, possibly avoiding surgery if the c…

This study tests whether adding low-dose radiation and an immunotherapy drug (cadonilimab) to standard chemotherapy can better control advanced nasopharyngeal cancer. About 380 adults aged 18-70 with newly diagnosed, advanced-stage disease will be randomly assigned to receive eit…

This study tests whether giving a combination of drugs (IBI308, bevacizumab, pemetrexed, and carboplatin) before surgery can shrink stage III non-small cell lung cancer enough to allow surgical removal. The goal is to see how many people can then have surgery. The study includes …

This study tests whether removing extra safety margins during adaptive radiation therapy can lower lung side effects while still controlling tumors. About 130 adults with early-stage non-small cell lung cancer or limited lung metastases will receive either standard or margin-free…

This study tests a new way to give the drug adebrelimab (either directly into the liver artery or through a vein) along with standard chemotherapy and another drug called bevacizumab for people with advanced liver cancer that has spread. The goal is to see if this combination can…

This study tests whether removing extra safety margins during MRI-guided radiation can safely treat lung cancer that has spread to the brain. About 168 adults with 1 to 10 brain metastases will receive precise, adaptive radiation without the usual buffer zone. The goal is to redu…

This study compares a reduced dose of radiation to the standard dose for low-risk areas in people with nasopharyngeal cancer. The goal is to see if the lower dose can control the cancer just as well while causing fewer side effects and improving quality of life. About 700 adults …

This study is for people with advanced liver cancer that has stopped responding to standard immunotherapy. It tests a new combination of two drugs (dalpiciclib and camrelizumab) to see if they can shrink tumors or slow the disease. About 30 participants will receive the treatment…

This study tests a new way of giving chemotherapy called adaptive therapy for people with advanced breast cancer that has gotten worse after standard treatments. The goal is to see if adjusting the dose over time can help control the cancer longer and with fewer side effects. Abo…

This study compares two types of minimally invasive lung surgery for people with early-stage non-small cell lung cancer: robot-assisted surgery (RATS) and video-assisted surgery (VATS). About 1,124 participants will be randomly assigned to one of the two procedures. The main goal…

This phase 3 trial tests whether adding an immunotherapy drug (PD-1 antibody) to standard chemoradiotherapy helps people with recurrent nasopharyngeal carcinoma live longer. About 212 participants whose cancer has returned after prior treatment and cannot be surgically removed wi…

This study tests a combination of three drugs (paclitaxel polymersomes, carboplatin, and adebelimab) given before surgery to people with a rare type of skin cancer called mucosal melanoma that can be removed. The goal is to see if this treatment shrinks the tumor enough to improv…

This study compares two chemotherapy combinations in 88 children (ages 6 months to 18 years) whose rhabdomyosarcoma has returned or not responded to prior treatment. One group receives doxorubicin liposome plus irinotecan (AI regimen), the other receives the standard VIT regimen.…

This study is for people with kidney cancer that has spread to up to 5 places in the body. It tests whether adding precise, high-dose radiation (SBRT) to standard drug therapy (targeted agents and immunotherapy) helps them live longer without the cancer growing. About 252 adults …

This phase 3 trial tests whether using MRI scans to guide radiation therapy can reduce lung side effects and improve outcomes for people with locally advanced non-small cell lung cancer. About 490 participants will receive radiation, chemotherapy, and immunotherapy, with half get…

This study is for people with advanced liver cancer whose first treatment (bevacizumab plus sintilimab) stopped working. It compares two second-line options: adding lenvatinib to the current regimen or switching to regorafenib plus a PD-1 inhibitor. The goal is to see which appro…

This study tests whether adding pianzumab to standard chemotherapy (AVD) helps more people with newly-diagnosed advanced classic Hodgkin lymphoma achieve remission. About 108 adults with stage III-IV or high-risk stage IIB disease will participate. The goal is to see if the combi…

This study tests a new combination of chemotherapy drugs for children and teens with hepatoblastoma, a rare liver cancer. The goal is to improve survival, especially for high-risk patients who currently have poor outcomes. About 100 participants under 18 will receive the treatmen…

This study tests a combination of two immune-boosting drugs (iparomlimab and tuvonralimab) plus a targeted antibody (nimotuzumab) in people with advanced nasopharyngeal cancer that got worse after standard first treatment. About 41 adults aged 18-70 will receive the therapy to se…

This study tests whether giving two drugs (pucotenlimab and vorolanib) before surgery can shrink kidney tumors enough to allow partial kidney removal instead of full removal. It includes 21 adults with high-risk clear cell renal cancer who need surgery but have tumors that make k…

This study tests whether adding two liver-directed treatments (chemoembolization and artery infusion) to standard immunotherapy can shrink tumors better in people with advanced liver cancer that cannot be removed by surgery. About 55 adults with good liver function and performanc…

This study tests whether combining zanubrutinib (a targeted pill) with rituximab (an antibody infusion) can shrink or control MALT lymphoma, a slow-growing cancer of the lymph nodes and organs. About 42 adults with newly diagnosed advanced disease or lymphoma that returned after …

This early-phase study tests an experimental drug called WTX212A, given alone or with radiation, in 12 people with advanced solid tumors. The goal is to see if it can shrink or control tumors and to check for side effects. Participants must be 18-75 and have a confirmed advanced …

This study is for people with a specific type of colorectal cancer (dMMR/MSI-H) that hasn't spread far. It tests giving an immunotherapy drug (toripalimab) with or without an anti-inflammatory drug (celecoxib) before surgery. The goal is to see if this approach can shrink or elim…

This study tests whether adding an immunotherapy drug (PD-1 inhibitor) to standard chemotherapy and radiation before surgery helps people with a certain type of esophageal cancer live longer. About 422 adults with stage T1-4aN1-3M0 or T3-4aN0M0 squamous cell esophageal cancer who…

This study tests a new drug called Becotatug Vedotin in children aged 2 to 18 with certain solid tumors that have come back or spread. The drug targets a protein called EGFR found on many cancer cells. The main goal is to see if the drug is safe and to find the best dose, while a…

This study tests whether cooling the kidney with ice slush during robot-assisted partial nephrectomy helps the kidney recover faster from the temporary loss of blood flow. About 310 adults with kidney cancer will be randomly assigned to receive either cold or warm ischemia during…

This study tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy in 148 adults with nasopharyngeal cancer that has come back or spread. The goal is to see if this mix can control the cancer longer and with manageable side effects. Participants must not have …

This study compares two different radiation schedules (shorter vs. standard) given alongside chemotherapy after initial chemo-immunotherapy for people with advanced esophageal cancer that cannot be removed by surgery. The goal is to see if the shorter schedule works as well or be…

This study tests whether adding the drug dalpiciclib to standard anti-HER2 and hormone therapy can delay cancer progression in people with a certain type of advanced breast cancer (HR-positive, HER2-positive). About 57 adults whose cancer has not worsened after initial treatment …

This study tests whether adding an oral probiotic (Biolosion) to standard chemotherapy before surgery can help eliminate more cancer cells in women with early-stage triple-negative breast cancer. About 192 participants will receive either standard treatment alone or standard trea…

This study tests a strategy to avoid removing the entire rectum in certain low rectal cancer patients who have had radiation. During surgery, a piece of the tumor is checked immediately under a microscope. If the cancer is only in the surface layer, the surgery stops and the pati…

This study tests two different chemotherapy combinations for people with extensive stage small cell lung cancer, a type that has spread widely. The goal is to see which combo works better at stopping the cancer from growing. About 90 adults who haven't had prior treatment for thi…

This study tests whether adding two drugs, toripalimab and surufatinib, to standard chemoradiotherapy can help people with limited-stage small cell lung cancer live longer without the cancer growing. About 47 adults aged 18 to 75 with this specific lung cancer type will receive t…

This study tests a combination of two drugs, eribulin and anlotinib, in people with HER2-negative advanced breast cancer who have already tried other treatments like antibody-drug conjugates but their cancer continued to grow. The goal is to see if this new pair can slow down or …

This study tests a combination of three drugs (surufatinib, sintilimab, and capecitabine) in people with advanced small bowel or appendix cancer that has spread and stopped responding to standard treatments. The goal is to see if this mix can shrink tumors or slow cancer growth. …

This study compares a newer, low-temperature plasma ablation method with standard high-frequency electrocautery surgery for people whose nasopharyngeal cancer has come back after initial treatment. About 500 participants will be randomly assigned to one of the two procedures. The…

This study tests a drug called toripalimab, which helps the immune system fight cancer, in people with advanced solid tumors that have specific gene changes (POLE or POLD-1 mutations) but not high microsatellite instability. About 35 adults who have not responded to standard trea…

This study tests a combination of two drugs (orelabrutinib and rituximab) followed by maintenance orelabrutinib in 32 adults with relapsed or refractory follicular lymphoma. The goal is to see how well the treatment shrinks tumors and how long it keeps the cancer under control. P…

This study is for people whose nasopharyngeal cancer has returned after initial treatment and cannot be removed by surgery. It compares two approaches: giving radiation right after a combination of immunotherapy and chemotherapy, versus waiting to see if more radiation is needed …

This study tests two drugs, QL1706 and lenvatinib, in people with advanced penile cancer that has already been treated. The goal is to shrink tumors and possibly make them removable by surgery. About 47 adults aged 18–80 will receive the drugs for up to a year, with the aim of co…

This study tests a drug called Toripalimab (an immunotherapy) combined with three different types of chemotherapy before standard radiation and chemo for people with advanced nasopharyngeal cancer. The goal is to find which combination works best to keep the cancer from coming ba…

This study tests whether giving a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus lenvatinib before surgery can shrink kidney tumors enough to allow a partial nephrectomy (removing only the tumor, not the whole kidney) in patients with localized renal c…

This study tests whether adding precise radiation to immunotherapy (camrelizumab) works better than immunotherapy alone for people with nasopharyngeal cancer that has spread to a few other spots. About 188 adults whose main tumor is under control will be randomly assigned to one …

This study tests a new drug combination (FOLFOX chemotherapy plus atezolizumab and bevacizumab) for people with advanced liver cancer whose disease got worse after initial treatment with atezolizumab and bevacizumab. About 30 adults with advanced liver cancer will receive this se…

This study tests a new drug called Cadonilimab in 28 people with advanced colorectal cancer that has a specific genetic feature (MSI-H or dMMR) and has stopped responding to standard immunotherapy. The drug targets two immune checkpoints (PD-1 and CTLA-4) to try to shrink tumors …

This study tests whether adding two drugs (serplulimab and bevacizumab) to standard chemotherapy improves outcomes for people with colorectal cancer that has spread to the liver and can be surgically removed. The trial involves 156 adults aged 18-75 with specific genetic types (R…

This study is for people with a type of advanced lung cancer that cannot be removed by surgery. It tests a new approach that combines chemotherapy, radiation, and two types of immunotherapy to see if it can control the cancer longer. The trial involves 56 participants and aims to…

This phase 3 trial tests whether adding an immunotherapy drug (pucotenlimab) to standard chemotherapy (CAPOX) improves outcomes for people with locally advanced rectal cancer. About 556 adults aged 18-75 will be randomly assigned to receive either the new combination or chemother…

This early-stage study tests a new treatment called IX001 TCR-T for people with advanced pancreatic cancer that has a specific genetic change (KRAS G12V). The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack the cancer. The…

This study tests a new two-pronged approach for people with B-cell lymphoma that has come back or not responded to standard treatments. It combines a personalized cell therapy (relmacabtagene autoleucel, a type of CAR-T) with an immunotherapy drug (sintilimab) to try to boost the…

This study tests a drug called apatinib combined with two chemotherapy drugs (irinotecan and temozolomide) in children aged 5 to 18 with neuroblastoma that has returned or not improved after standard treatment. The goal is to see if the combination can shrink tumors and help chil…

This study tests whether adding prostate cryoablation (freezing the tumor) and a low-dose chemotherapy drug (cyclophosphamide) to standard hormone therapy can delay cancer progression in men with newly diagnosed metastatic prostate cancer. About 104 men aged 18-80 will receive th…

This study tests two ways to treat lung cancer that has spread to the brain. One group gets focused radiation plus a drug called bevacizumab; the other gets whole-brain radiation that tries to protect the memory center. The goal is to see which approach better controls the brain …

This study tests a new method to find the original location of cancers that have spread without a known starting point. Researchers use a computer model to analyze DNA patterns from tumor samples. The goal is to help doctors choose the right treatment for each patient. The study …

This study tests a new imaging technique called photoacoustic tomography (PACT) to better detect lower extremity artery disease (LEAD), a condition where leg arteries become narrowed or blocked. Current methods often miss the disease, leading to serious complications. The study w…

This study tests whether adding Houyanqing Oral Liquid to standard care can prevent or reduce severe mouth sores caused by radiation therapy in people with nasopharyngeal cancer. About 386 patients will be randomly assigned to receive either the herbal liquid plus usual treatment…

This study tests whether inhaling a drug called penehyclidine hydrochloride before surgery can prevent breathing complications in children aged 3 to 7 who are at higher risk. The trial involves 204 kids undergoing minor eye surgery with sevoflurane anesthesia. Researchers will co…

This study tests if rinsing the rectum with fluid during keyhole surgery can lower the chance of rectal cancer returning. About 1,600 adults with mid-to-low rectal cancer will be randomly assigned to receive the wash or not. Researchers will track cancer recurrence, survival, and…

This study tests whether giving radiation only to the specific neck areas where cancer has spread can reduce side effects and improve quality of life for people with nasopharyngeal carcinoma, without affecting survival. About 470 newly diagnosed patients will be assigned to eithe…

This study tests whether Xinlikang capsules can reduce severe fatigue and help the immune system recover in people with diffuse large B-cell lymphoma who have finished chemotherapy and are in remission. About 80 adults will receive either the capsule or a placebo for several week…

This study reviews medical records of 446 people with hepatitis B-related liver failure who received stem cell therapy. Researchers want to find out why some patients did not improve. The goal is to identify factors that affect treatment success so future patients can benefit mor…

This study is following 2000 adults with moderate or severe mitral regurgitation (a leaky heart valve) to identify factors that raise the risk of death or heart failure. Researchers will use this information to build a model that helps doctors make better treatment decisions. Par…

This study tests a 4-week online program designed to help parents of children aged 3-6 build healthy habits like physical activity, handwashing, and less screen time. Researchers will compare parents who use the program right away with those on a waitlist. The goal is to see if t…

This study follows 2000 people with IgA nephropathy who still have good kidney function. Researchers will test blood and urine samples to find biomarkers that might predict if and when kidney disease gets worse. The goal is to better understand the disease, not to test a new trea…

This study is for people with hepatitis B who are at high risk for liver cancer. Researchers will use artificial intelligence and different types of health data to better predict who might develop liver cancer and when. The goal is to catch cancer earlier and improve survival. Th…

This study tests whether an AI-powered teaching agent can help medical and nursing graduate students learn machine learning and data mining more effectively. About 56 students will use the AI tool for real-time help, study planning, and project guidance. Their grades and confiden…

This study follows 30,000 adults diagnosed with various forms of coronary artery disease to see how different risk factors affect long-term survival. Researchers will track deaths from any cause and from heart-related problems. The goal is to better understand what influences out…

This study looks at two different methods (one-needle vs two-needle) for placing a PICC line, a long-term IV used for treatments like chemotherapy. About 284 adults will take part to see which method leads to fewer complications like bleeding, infection, or blood clots. The goal …

This study looks at how differences in HER2 levels and location within tumors affect how well the drug trastuzumab deruxtecan works in people with metastatic breast cancer. Researchers will follow 800 patients to see if these HER2 patterns are linked to longer survival without th…

This study looks at 50 people with nasopharyngeal cancer that has come back or spread. Researchers will use advanced lab tests (multi-omics) to see if they can predict how well a combination of chemotherapy, radiation, and immunotherapy works. The goal is to find better ways to p…

This study looks at two ways to place a thin, flexible tube (called a PICC) in cancer patients who need long-term IV treatments. One method uses magnetic tracking, and the other uses heart signals (ECG) to guide the tube to the right spot. Researchers want to see which method wor…

This study is following 4,000 adults diagnosed with heart valve disease to discover new risk factors and understand how certain natural chemicals (metabolites) in the body influence the disease. Researchers will track participants over time and test tissue samples. The goal is to…

This study looks at whether a blood test can help doctors track neuroblastoma, a type of childhood cancer. Researchers will collect blood samples from 200 patients over time to look for tiny bits of tumor DNA. The goal is to see if changes in this DNA match how the disease is res…